Stanford Office of Technology Licensing, Palo Alto, CA, US
Stanford researchers have developed a 3D printing technology (“Hybprinter”) that can be used to form hybrid multi-material constructs incorporating a wide spectrum of materials (rigid and soft) and bioagents (such as cells and growth factors) with controlled spatial distribution across the hybrid structure. Due to its layer-by-layer manufacturing nature, Hybprinter enables the combination of cell-laden soft and hard biomaterials with a controlled spatial distribution for regenerative medicine applications. For instance, Hybprinter can be used to form connectable vascularized bone scaffolds composed of rigid, porous, osteoconductive load-bearing scaffolds and soft hydrogel vascular conduits (or channels containing soft hydrogel) with a high diffusion rate, thus eliminating the issues normally associated with surgical anastomosis of vascular grafts. The Hybprinting process also ensures high cell viability across the fabricated tissue engineering constructs.
Primary Application Area: Biotech, Pharma, Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 4
Organization Type: Academic/Gov Lab
Showcase Booth #: 522
GOVT/EXTERNAL FUNDING SOURCES